Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 6/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29233712 | 0.85 | PDK1 (0.47) | PDK1HRH3IRAK4ALDH1A1ACKR3 | |
| SCHEMBL16770006 | 0.84 | PDK1 (0.46) | PDK1HRH3IRAK4ALDH1A1ACKR3 | |
| SCHEMBL16770005 | 0.84 | PDK1 (0.46) | PDK1HRH3IRAK4ACKR3SLC6A2 | |
| SCHEMBL16770003 | 0.83 | PDK1 (0.45) | PDK1HRH3IRAK4ACKR3SLC6A2 | |
| SCHEMBL14782902 | 0.81 | PDK1 (0.72) | PDK1HRH3ALDH1A1NLRP3SYK | |
| SCHEMBL17014690 | 0.80 | PDK1 (0.58) | PDK1HRH3ALDH1A1NLRP3SYK | |
| SCHEMBL14126497 | 0.80 | PDK1 (0.58) | PDK1ALDH1A1NLRP3LMNAPOLB | |
| SCHEMBL16769863 | 0.79 | PDK1 (0.42) | PDK1HRH3IRAK4ALDH1A1ACKR3 | |
| SCHEMBL13887587 | 0.77 | WNT1 (0.38) | PDK1HRH3IRAK4ACKR3SLC6A2 | |
| SCHEMBL7925158 | 0.77 | PDK1 (0.56) | PDK1HRH3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2884982-B1 | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9353066-B2 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | PDK1 721/4885HRH3 653/4885IRAK4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.